Literature DB >> 32231915

RT-QuIC Assays in Humans … and Animals.

Steven Collins1,2,3, Shannon Sarros1,3.   

Abstract

Prion diseases are neurodegenerative diseases affecting both humans and animal species. The phenotypic spectrum is broad and includes Creutzfeldt-Jakob disease (CJD) and its variant zoonotic form (vCJD) in humans, while in animals, scrapie of sheep and goats, bovine spongiform encephalopathy and chronic wasting disease of deer, elk and moose are naturally occurring forms. Transmission and pathogenesis appear causally linked to the misfolding of the normal form of the prion protein (PrPC) into disease associated conformers (PrPD), the latter enriched in β-strand secondary structure. Over the past 10 years two protein amplification techniques, the protein misfolding cyclic amplification (PMCA) assay and real-time quaking induced conversion (RT-QuIC) assay have been developed and successfully deployed in prion biology across a range of scientific and clinical applications, including generation of de novo prions, quantitation of prion infectivity and ultra-sensitive detection of PrPD. While PMCA utilises sonication to facilitate protein amplification, RT-QuIC employs vigorous shaking to achieve this outcome, with both techniques sharing the ability to amplify miniscule quantities of PrPD seed present in various tissues and body fluids to levels detectable using routine biochemical methods. The enhanced specificity of the RT-QuIC for detection of PrPD in cerebrospinal fluid (CSF) has spawned international collaborations to rigorously assess and validate the assay for clinical diagnostic purposes. In parallel with collaborative CSF validation studies have been successful efforts to refine the RT-QuIC allowing its use for more accessible body fluids or tissues such as urine and nasal brushings, as well as promote higher sample throughput, shorten assay times and offer accurate quantification of PrPD even at levels below those detectable by animal bioassays. Animal studies support the generic capacity of the RT-QuIC for PrPD detection, underpinning the utility of this assay for studying prion disease and the high likelihood of inter-convertibility of technical refinements for human and animal use. ©2016 Food Safety Commission, Cabinet Office, Government of Japan.

Entities:  

Keywords:  RT-QuIC; animal. diagnostics; human; prion disease

Year:  2016        PMID: 32231915      PMCID: PMC6989204          DOI: 10.14252/foodsafetyfscj.2016020

Source DB:  PubMed          Journal:  Food Saf (Tokyo)        ISSN: 2187-8404


  22 in total

1.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.

Authors:  G P Saborio; B Permanne; C Soto
Journal:  Nature       Date:  2001-06-14       Impact factor: 49.962

2.  Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking.

Authors:  Ryuichiro Atarashi; Jason M Wilham; Leah Christensen; Andrew G Hughson; Roger A Moore; Lisa M Johnson; Henry A Onwubiko; Suzette A Priola; Byron Caughey
Journal:  Nat Methods       Date:  2008-03       Impact factor: 28.547

3.  An analytical solution to the kinetics of breakable filament assembly.

Authors:  Tuomas P J Knowles; Christopher A Waudby; Glyn L Devlin; Samuel I A Cohen; Adriano Aguzzi; Michele Vendruscolo; Eugene M Terentjev; Mark E Welland; Christopher M Dobson
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

4.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.

Authors:  Ryuichiro Atarashi; Katsuya Satoh; Kazunori Sano; Takayuki Fuse; Naohiro Yamaguchi; Daisuke Ishibashi; Takehiro Matsubara; Takehiro Nakagaki; Hitoki Yamanaka; Susumu Shirabe; Masahito Yamada; Hidehiro Mizusawa; Tetsuyuki Kitamoto; Genevieve Klug; Amelia McGlade; Steven J Collins; Noriyuki Nishida
Journal:  Nat Med       Date:  2011-01-30       Impact factor: 53.440

5.  Hyperekplexia as the presenting symptom of Creutzfeldt-Jakob disease.

Authors:  Sudarshini Ramanathan; Victor S C Fung; Alen Bielich; Lynette Masters; Robert R Russo; Michael E Buckland; Shannon Sarros; Genevieve M J A Klug; Steven Collins; Stephen W Reddel
Journal:  Neurol Clin Pract       Date:  2015-12

6.  A test for Creutzfeldt-Jakob disease using nasal brushings.

Authors:  Christina D Orrú; Matilde Bongianni; Giovanni Tonoli; Sergio Ferrari; Andrew G Hughson; Bradley R Groveman; Michele Fiorini; Maurizio Pocchiari; Salvatore Monaco; Byron Caughey; Gianluigi Zanusso
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

7.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

Review 8.  Transmissible spongiform encephalopathies.

Authors:  Steven J Collins; Victoria A Lawson; Colin L Masters
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

9.  Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease.

Authors:  B J Steinhoff; S Räcker; G Herrendorf; S Poser; S Grosche; I Zerr; H Kretzschmar; T Weber
Journal:  Arch Neurol       Date:  1996-02

10.  Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease.

Authors:  Lynne I McGuire; Alexander H Peden; Christina D Orrú; Jason M Wilham; Nigel E Appleford; Gary Mallinson; Mary Andrews; Mark W Head; Byron Caughey; Robert G Will; Richard S G Knight; Alison J E Green
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

View more
  2 in total

1.  Subject fields in Food Safety during 10 years.

Authors:  Yasushi Yamazoe; Shigeki Yamamoto; Midori Yoshida; Toru Kawanishi; Susumu Kumagai
Journal:  Food Saf (Tokyo)       Date:  2021-06-25

2.  Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies.

Authors:  Mie Kristine Just; Hjalte Gram; Vasileios Theologidis; Poul Henning Jensen; K Peter R Nilsson; Mikael Lindgren; Karoline Knudsen; Per Borghammer; Nathalie Van Den Berge
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.